Clinical trial
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in…
NCT00234416 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00234416 |
|---|---|
| Title | IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer |
| Official title | A Trial to Evaluate ZD1839 (IRESSA) in Combination With Radiotherapy & Gemcitabine as First-Line Treatment in Patients With Locally Advanced Pancreatic Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, Gemcitabine |
| Enrollment | 45 |
| Start date | Aug 1, 2002 |
| Completion | Mar 1, 2005 |
| First posted | Oct 7, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: